## Thomas J Giordano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7488077/publications.pdf

Version: 2024-02-01

206 papers

27,528 citations

72 h-index 161

211 all docs

211 docs citations

times ranked

211

32567 citing authors

g-index

#	Article	IF	CITATIONS
1	Targeted Mutational Analysis of Cortisol-Producing Adenomas. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e594-e603.	3.6	13
2	Histopathology and Genetic Causes of Primary Aldosteronism in Young Adults. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2473-2482.	3.6	4
3	The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. Journal of the National Cancer Institute, 2021, 113, 27-37.	6.3	17
4	International Histopathology Consensus for Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 42-54.	3.6	127
5	Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Human Pathology, 2021, 110, 50-61.	2.0	18
6	Molecular Pathogenesis of Thyroid Neoplasia. , 2021, , 181-185.e5.		1
7	The Age-Dependent Changes of the Human Adrenal Cortical Zones Are Not Congruent. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1389-1397.	3.6	11
8	What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics. Endocrine Pathology, 2021, 32, 102-133.	9.0	33
9	Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas. American Journal of Surgical Pathology, 2021, 45, 1264-1273.	3.7	19
10	Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. Proceedings of the National Academy of Sciences of the United States of America, $2021,118,$	7.1	136
11	Multiplatform molecular test performance in indeterminate thyroid nodules. Diagnostic Cytopathology, 2020, 48, 1254-1264.	1.0	73
12	Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). Journal of Thoracic Oncology, 2020, 15, 1748-1757.	1.1	21
13	Targeted RNAseq of Formalin-Fixed Paraffin-Embedded Tissue to Differentiate Among Benign and Malignant Adrenal Cortical Tumors. Hormone and Metabolic Research, 2020, 52, 607-613.	1.5	9
14	Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma. Journal of Biological Chemistry, 2020, 295, 8834-8845.	3.4	21
15	Somatic <i>CACNA1H</i> Mutation As a Cause of Aldosterone-Producing Adenoma. Hypertension, 2020, 75, 645-649.	2.7	69
16	Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations. Modern Pathology, 2020, 33, 1264-1274.	5.5	96
17	Next-generation RNA Sequencing–based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms. European Urology, 2020, 78, 63-74.	1.9	57
18	Identification of Somatic Mutations in CLCN2 in Aldosterone-Producing Adenomas. Journal of the Endocrine Society, 2020, 4, bvaa123.	0.2	27

#	Article	IF	CITATIONS
19	Adjuvant Radiation Improves Recurrence-Free Survival and Overall Survival in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3743-3750.	3.6	35
20	Interobserver Variability in the Histopathologic Assessment of Extrathyroidal Extension of Well Differentiated Thyroid Carcinoma Supports the New American Joint Committee on Cancer Eighth Edition Criteria for Tumor Staging. Thyroid, 2019, 29, 619-624.	4.5	22
21	Targeted Assessment of <i>GOS2</i> Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma. Clinical Cancer Research, 2019, 25, 3276-3288.	7.0	51
22	Genetic Characteristics of Aldosterone-Producing Adenomas in Blacks. Hypertension, 2019, 73, 885-892.	2.7	121
23	Longitudinal patterns of recurrence in patients with adrenocortical carcinoma. Surgery, 2019, 165, 186-195.	1.9	47
24	Genomic Applications in Thyroid Cancer. , 2019, , 325-334.		1
25	Genetics of aldosterone-producing adenomas with pathogenic KCNJ5 variants. Endocrine-Related Cancer, 2019, 26, 463-470.	3.1	7
26	Somatic mutations in adrenocortical carcinoma with primary aldosteronism or hyperreninemic hyperaldosteronism. Endocrine-Related Cancer, 2019, 26, 217-225.	3.1	10
27	Pioglitazone Therapy of PAX8-PPAR $\hat{I}^3$ Fusion Protein Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1277-1281.	3.6	22
28	Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms. Endocrine Pathology, 2018, 29, 137-149.	9.0	45
29	The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes. Human Pathology, 2018, 71, 47-54.	2.0	39
30	Genomic Hallmarks of Thyroid Neoplasia. Annual Review of Pathology: Mechanisms of Disease, 2018, 13, 141-162.	22.4	50
31	Transcriptional targeting of oncogene addiction in medullary thyroid cancer. JCI Insight, 2018, 3, .	5.0	19
32	Targeted Molecular Characterization of Aldosterone-Producing Adenomas in White Americans. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3869-3876.	3.6	122
33	Tumors of the Adrenal Glands; Pathology and Genetics. , 2018, , 18-18.		1
34	65 YEARS OF THE DOUBLE HELIX: Classification of endocrine tumors in the age of integrated genomics. Endocrine-Related Cancer, 2018, 25, T171-T187.	3.1	6
35	Change in Diagnostic Criteria for Noninvasive Follicular Thyroid Neoplasm With Papillarylike Nuclear Features. JAMA Oncology, 2018, 4, 1125.	7.1	151
36	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	16.8	532

#	Article	IF	Citations
37	Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism. Clinical Endocrinology, 2017, 87, 665-672.	2.4	68
38	Gastrin Induces Nuclear Export and Proteasome Degradation of Menin in Enteric Glial Cells. Gastroenterology, 2017, 153, 1555-1567.e15.	1.3	28
39	An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma. American Journal of Surgical Pathology, 2016, 40, 569-576.	3.7	75
40	Follicular cell thyroid neoplasia. Current Opinion in Oncology, 2016, 28, 1-4.	2.4	37
41	Double adrenocortical adenomas harboring independent KCNJ5 and PRKACA somatic mutations. European Journal of Endocrinology, 2016, 175, K1-K6.	3.7	37
42	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. JAMA Oncology, 2016, 2, 1023.	7.1	1,192
43	EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression. Human Molecular Genetics, 2016, 25, ddw136.	2.9	37
44	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 2016, 29, 723-736.	16.8	482
45	Molecular classification of thyroid lesions by combined testing for miRNA gene expression and somatic gene alterations. Journal of Pathology: Clinical Research, 2016, 2, 93-103.	3.0	47
46	Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3345-3352.	3.6	21
47	Genetic variants in thyroid cancer distant metastases. Endocrine-Related Cancer, 2016, 23, L33-L36.	3.1	9
48	Association of <i>BRAF<sup>V600E</sup></i> Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers. Thyroid, 2016, 26, 532-542.	4.5	50
49	Molecular Heterogeneity in Aldosterone-Producing Adenomas. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 999-1007.	3.6	74
50	Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. European Journal of Endocrinology, 2016, 174, 601-609.	3.7	168
51	Notch signaling regulates gastric antral LGR 5 stem cell function. EMBO Journal, 2015, 34, 2522-2536.	7.8	74
52	Role and regulation of coordinately expressed i> de novo (i> purine biosynthetic enzymes < i> PPAT < / i> and < i> PAICS < / i> in lung cancer. Oncotarget, 2015, 6, 23445-23461.	1.8	80
53	Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4591-9.	7.1	256
54	Implications of the TCGA Genomic Characterization of Papillary Thyroid Carcinoma for Thyroid Pathology: Does Follicular Variant Papillary Thyroid Carcinoma Exist?. Thyroid, 2015, 25, 1-2.	<b>4.</b> 5	54

#	Article	IF	CITATIONS
55	Metastasis-associated <i>MCL1</i> and <i>P16</i> copy number alterations dictate resistance to vemurafenib in a <i>BRAFV600E</i> patient-derived papillary thyroid carcinoma preclinical model. Oncotarget, 2015, 6, 42445-42467.	1.8	40
56	Pinpointing a hotspot in adrenal Cushing syndrome. Nature Reviews Endocrinology, 2014, 10, 447-448.	9.6	6
57	Adrenocortical Carcinoma. Endocrine Reviews, 2014, 35, 282-326.	20.1	671
58	The Cancer Genome Atlas Research Network: A Sight to Behold. Endocrine Pathology, 2014, 25, 362-365.	9.0	47
59	Poorly Differentiated Neuroendocrine Carcinomas of the Pancreas. American Journal of Surgical Pathology, 2014, 38, 437-447.	3.7	216
60	Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens. Human Pathology, 2014, 45, 1339-1347.	2.0	47
61	Genetics of Adrenal Tumors. , 2014, , 313-321.		0
62	Assessing Biological Aggression in Adrenocortical Neoplasia. Surgical Pathology Clinics, 2014, 7, 533-541.	1.7	4
63	An oncocytic adrenal tumour in a patient with Birtâ€Hoggâ€Dubé syndrome. Clinical Endocrinology, 2014, 80, 925-927.	2.4	14
64	Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non–small cell lung cancer. Journal of Surgical Research, 2014, 187, 6-13.	1.6	23
65	Myeloid-Derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2. Immunity, 2013, 39, 611-621.	14.3	366
66	Does <i>BRAF</i> V600E Mutation Predict Aggressive Features in Papillary Thyroid Cancer? Results From Four Endocrine Surgery Centers. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3702-3712.	3.6	55
67	Distinct Gene Expression Profiles of Viral- and Nonviral-Associated Merkel Cell Carcinoma Revealed by Transcriptome Analysis. Journal of Investigative Dermatology, 2013, 133, 936-945.	0.7	98
68	CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells. Lung Cancer, 2013, 82, 477-484.	2.0	37
69	Transcriptome Profiling Identifies HMGA2 as a Biomarker of Melanoma Progression and Prognosis. Journal of Investigative Dermatology, 2013, 133, 2585-2592.	0.7	96
70	Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer. Head and Neck, 2013, 35, 1083-1090.	2.0	30
71	Funding Anatomic Pathology Research: A Retrospective Analysis of an Intramural Funding Mechanism. Archives of Pathology and Laboratory Medicine, 2013, 137, 1270-1273.	2.5	3
72	Adrenocortical Carcinoma Is a Lynch Syndrome–Associated Cancer. Journal of Clinical Oncology, 2013, 31, 3012-3018.	1.6	153

#	Article	IF	CITATIONS
73	Three Endocrine Neoplasms: An Unusual Combination of Pheochromocytoma, Pituitary Adenoma, and Papillary Thyroid Carcinoma. Thyroid, 2012, 22, 430-436.	4.5	9
74	Activation of GATA binding protein 6 ( $\langle i \rangle$ GATA6 $\langle i \rangle$ ) sustains oncogenic lineage-survival in esophageal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 4251-4256.	7.1	76
75	Progression to Adrenocortical Tumorigenesis in Mice and Humans through Insulin-Like Growth Factor 2 and $\hat{l}^2$ -Catenin. American Journal of Pathology, 2012, 181, 1017-1033.	3.8	154
76	Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer, 2012, 77, 265-271.	2.0	58
77	Upregulated JAG1 Enhances Cell Proliferation in Adrenocortical Carcinoma. Clinical Cancer Research, 2012, 18, 2452-2464.	7.0	33
78	Gene expression profiling in adrenocortical neoplasia. Molecular and Cellular Endocrinology, 2012, 351, 111-117.	3.2	31
79	Familial renal cancer as an indicator of hereditary leiomyomatosis and renal cell cancer syndrome. Familial Cancer, 2012, 11, 115-121.	1.9	17
80	Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nature Medicine, $2011$ , $17$ , $1646$ - $1651$ .	30.7	301
81	The Argument for Mitotic Rate-based Grading for the Prognostication of Adrenocortical Carcinoma. American Journal of Surgical Pathology, 2011, 35, 471-473.	3.7	33
82	Progression of BRAF-induced thyroid cancer is associated with epithelial–mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene, 2011, 30, 3153-3162.	5.9	160
83	Pioglitazone Induces a Proadipogenic Antitumor Response in Mice with PAX8-PPARÎ <sup>3</sup> Fusion Protein Thyroid Carcinoma. Endocrinology, 2011, 152, 4455-4465.	2.8	52
84	Stromal LRP1 in Lung Adenocarcinoma Predicts Clinical Outcome. Clinical Cancer Research, 2011, 17, 2426-2433.	7.0	39
85	<i>CYP24A1</i> Is an Independent Prognostic Marker of Survival in Patients with Lung Adenocarcinoma. Clinical Cancer Research, 2011, 17, 817-826.	7.0	96
86	Gene Expression Differences between Colon and Rectum Tumors. Clinical Cancer Research, 2011, 17, 7303-7312.	7.0	69
87	Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1439-1444.	7.1	87
88	Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbeck's Archives of Surgery, 2010, 395, 955-961.	1.9	65
89	Human papillomavirus is not associated with colorectal cancer in a large international study. Cancer Causes and Control, 2010, 21, 737-743.	1.8	60
90	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nature Medicine, 2010, 16, 793-798.	30.7	436

#	Article	IF	Citations
91	Decreased Selenium-Binding Protein 1 in Esophageal Adenocarcinoma Results from Posttranscriptional and Epigenetic Regulation and Affects Chemosensitivity. Clinical Cancer Research, 2010, 16, 2009-2021.	7.0	69
92	IRS1 Regulation by Wnt/ $\hat{l}^2$ -Catenin Signaling and Varied Contribution of IRS1 to the Neoplastic Phenotype. Journal of Biological Chemistry, 2010, 285, 1928-1938.	3.4	50
93	A Phase II Study of Imatinib in Patients with Advanced Anaplastic Thyroid Cancer. Thyroid, 2010, 20, 975-980.	4.5	116
94	Classification of adrenal cortical tumors: Promise of the â€~molecular' approach. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 887-892.	4.7	6
95	GSK3Î <sup>2</sup> and Î <sup>2</sup> -Catenin Modulate Radiation Cytotoxicity in Pancreatic Cancer. Neoplasia, 2010, 12, 357-365.	5.3	43
96	Curcumin Promotes Apoptosis, Increases Chemosensitivity, and Inhibits Nuclear Factor κB in Esophageal Adenocarcinoma. Translational Oncology, 2010, 3, 99-108.	3.7	89
97	B-Raf <sup>V600E</sup> and thrombospondin-1 promote thyroid cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10649-10654.	7.1	164
98	Adrenocortical Tumors: An Integrated Clinical, Pathologic, and Molecular Approach at the University of Michigan. Archives of Pathology and Laboratory Medicine, 2010, 134, 1440-1443.	2.5	20
99	Benign Lung Tumors. , 2010, , 1171-1185.		0
100	Development of a Multiplex Quantitative PCR Signature to Predict Progression in Non–Muscle-Invasive Bladder Cancer. Cancer Research, 2009, 69, 3810-3818.	0.9	33
101	Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biology and Therapy, 2009, 8, 2042-2050.	3.4	78
102	Paired Box Gene 8-Peroxisome Proliferator-Activated Receptor- $\hat{l}^3$ Fusion Protein and Loss of Phosphatase and Tensin Homolog Synergistically Cause Thyroid Hyperplasia in Transgenic Mice. Endocrinology, 2009, 150, 5181-5190.	2.8	25
103	Preclinical Targeting of the Type I Insulin-Like Growth Factor Receptor in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 204-212.	3.6	177
104	Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway. Clinical Cancer Research, 2009, 15, 2829-2839.	7.0	57
105	Thyroid Carcinoma Metastasis to Skull with Infringement of Brain: Treatment with Radioiodine. Thyroid, 2009, 19, 297-303.	4.5	30
106	Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling. Clinical Cancer Research, 2009, 15, 668-676.	7.0	356
107	Location of ectopic adrenocortical hormoneâ€secreting tumors causing Cushing's syndrome in the paranasal sinuses. Head and Neck, 2009, 31, 699-706.	2.0	14
108	An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nature Biotechnology, 2009, 27, 1005-1011.	17.5	69

#	Article	IF	Citations
109	SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genetics, 2009, 41, 1238-1242.	21.4	862
110	Differential Protein Mapping of Ovarian Serous Adenocarcinomas: Identification of Potential Markers for Distinct Tumor Stage. Journal of Proteome Research, 2009, 8, 1452-1463.	3.7	32
111	Upregulated INHBA Expression May Promote Cell Proliferation and Is Associated with Poor Survival in Lung Adenocarcinoma. Neoplasia, 2009, 11, 388-396.	5.3	125
112	INHBA Overexpression Promotes Cell Proliferation and May Be Epigenetically Regulated in Esophageal Adenocarcinoma. Journal of Thoracic Oncology, 2009, 4, 455-462.	1.1	53
113	Genome-Wide Studies in Adrenocortical Neoplasia. , 2009, , 483-491.		0
114	First Description of Parathyroid Disease in Multiple Endocrine Neoplasia 2A Syndrome. Endocrine Pathology, 2008, 19, 289-293.	9.0	4
115	Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas.  Proteomics - Clinical Applications, 2008, 2, 571-584.	1.6	14
116	Utility of cytology microarray constructed from effusion cell blocks for immunomarker validation. Cancer, 2008, 114, 300-306.	4.1	21
117	Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 2008, 455, 1069-1075.	27.8	2,694
118	C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene, 2008, 27, 6623-6634.	5.9	178
119	Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine, 2008, 14, 822-827.	30.7	1,015
120	Genome-Wide Studies in Thyroid Neoplasia. Endocrinology and Metabolism Clinics of North America, 2008, 37, 311-331.	3.2	9
121	Transcriptome analysis of endocrine tumors: Clinical perspectives. Annales D'Endocrinologie, 2008, 69, 130-134.	1.4	2
122	EML4-ALK Fusion Lung Cancer: A Rare Acquired Event. Neoplasia, 2008, 10, 298-302.	5.3	231
123	Genetic Changes of Wnt Pathway Genes Are Common Events in Metaplastic Carcinomas of the Breast. Clinical Cancer Research, 2008, 14, 4038-4044.	7.0	144
124	Evaluation of Telomere Length Maintenance Mechanisms in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1442-1449.	3.6	45
125	Perspectives for Improved and More Accurate Classification of Thyroid Epithelial Tumors. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3286-3294.	3.6	39
126	AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2008, 3, 1236-1244.	1.1	47

#	Article	IF	CITATIONS
127	Genetic variation in 8q24 associated with risk of colorectal cancer. Cancer Biology and Therapy, 2007, 6, 1143-1147.	3.4	70
128	HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. Endocrine-Related Cancer, 2007, 14, 445-452.	3.1	70
129	Autoantibody Profiles Reveal Ubiquilin 1 as a Humoral Immune Response Target in Lung Adenocarcinoma. Cancer Research, 2007, 67, 3461-3467.	0.9	86
130	Comparative Proteomics Analysis of Barrett Metaplasia and Esophageal Adenocarcinoma Using Two-dimensional Liquid Mass Mapping. Molecular and Cellular Proteomics, 2007, 6, 987-999.	3.8	33
131	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer, 2007, 109, 957-965.	4.1	66
132	NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nature Medicine, 2007, 13, 62-69.	30.7	296
133	Characterizing the cancer genome in lung adenocarcinoma. Nature, 2007, 450, 893-898.	27.8	1,020
134	p53-Mediated Activation of miRNA34 Candidate Tumor-Suppressor Genes. Current Biology, 2007, 17, 1298-1307.	3.9	1,045
135	Leiomyoma of the Adrenal Gland Presenting as a Non-Functioning Adrenal Incidentaloma: Case Report and Review of the Literature. Endocrine Pathology, 2007, 18, 239-243.	9.0	16
136	Odontogenic Keratocysts Arise from Quiescent Epithelial Rests and Are Associated with Deregulated Hedgehog Signaling in Mice and Humans. American Journal of Pathology, 2006, 169, 806-814.	3.8	34
137	Expression and Effect of Inhibition of the Ubiquitin-Conjugating Enzyme E2C on Esophageal Adenocarcinoma. Neoplasia, 2006, 8, 1062-1071.	5.3	56
138	Identification of a Specific Vimentin isoform that Induces an Antibody Response in Pancreatic Cancer. Biomarker Insights, 2006, 1, 117727190600100.	2.5	21
139	Molecular Profiling and Personalized Predictive Pathology. American Journal of Surgical Pathology, 2006, 30, 402-404.	3.7	7
140	Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas. American Journal of Surgical Pathology, 2006, 30, 216-222.	3.7	467
141	Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatric Blood and Cancer, 2006, 46, 614-623.	1.5	48
142	Molecular pathology of adrenal cortical tumors: Separating adenomas from carcinomas. Endocrine Pathology, 2006, 17, 355-364.	9.0	23
143	Multiple forms of genetic instability within a 2-Mb chromosomal segment of 3q26.3-q27 are associated with development of esophageal adenocarcinoma. Genes Chromosomes and Cancer, 2006, 45, 319-331.	2.8	18
144	Delineation, Functional Validation, and Bioinformatic Evaluation of Gene Expression in Thyroid Follicular Carcinomas with the PAX8-PPARG Translocation. Clinical Cancer Research, 2006, 12, 1983-1993.	7.0	125

#	Article	IF	CITATIONS
145	The Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy Rule: Implications for Clinical Research. Annual Review of Medicine, 2006, 57, 575-590.	12.2	73
146	Morphologic and Molecular Classification of Human Cancer., 2006, , 10-20.		2
147	Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancer. Biomarker Insights, 2006, 1, 175-183.	2.5	18
148	Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene, 2005, 24, 6646-6656.	5.9	354
149	Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell, 2005, 8, 13-23.	16.8	338
150	Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC Bioinformatics, 2005, 6, 26.	2.6	109
151	Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer, 2005, 103, 830-838.	4.1	81
152	Ganglioneuroma Manifesting as an Incidental Adrenal Mass in an Adult With Turner's Syndrome. Endocrine Practice, 2005, 11, 382-384.	2.1	4
153	Analysis of Tumor-Host Interactions by Gene Expression Profiling of Lung Adenocarcinoma Xenografts Identifies Genes Involved in Tumor Formation. Molecular Cancer Research, 2005, 3, 119-129.	3.4	57
154	CDX2 Polymorphisms, RNA Expression, and Risk of Colorectal Cancer. Cancer Research, 2005, 65, 5488-5492.	0.9	29
155	Interferon Regulatory Factor 1 (IRF-1) and IRF-2 Expression in Breast Cancer Tissue Microarrays. Journal of Interferon and Cytokine Research, 2005, 25, 587-594.	1.2	44
156	Phosphorylated FADD induces NF- $\hat{I}^{\circ}$ B, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 12507-12512.	7.1	122
157	Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocrine-Related Cancer, 2005, 12, 667-680.	3.1	354
158	CDX2-regulated expression of iron transport protein hephaestin in intestinal and colonic epithelium. Gastroenterology, 2005, 128, 946-961.	1.3	45
159	Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clinical Cancer Research, 2005, 11, 565-72.	7.0	125
160	Molecular Profiling and the Identification of Genes Associated With Metastatic Oral Cavity/Pharynx Squamous Cell Carcinoma. JAMA Otolaryngology, 2004, 130, 295.	1.2	106
161	Cell Surface Expression of Epidermal Growth Factor Receptor and Her-2 with Nuclear Expression of Her-4 in Primary Osteosarcoma. Cancer Research, 2004, 64, 2047-2053.	0.9	135
162	An Autoantibody-Mediated Immune Response to Calreticulin Isoforms in Pancreatic Cancer. Cancer Research, 2004, 64, 5504-5510.	0.9	119

#	Article	IF	Citations
163	Overexpression of 5-Lipoxygenase in Rat and Human Esophageal Adenocarcinoma and Inhibitory Effects of Zileuton and Celecoxib on Carcinogenesis. Clinical Cancer Research, 2004, 10, 6703-6709.	7.0	94
164	Malignant pheochromocytoma: current status and initiatives for future progress. Endocrine-Related Cancer, 2004, 11, 423-436.	3.1	299
165	Melanoma-Associated Antigens in Esophageal Adenocarcinoma. Clinical Cancer Research, 2004, 10, 5708-5716.	7.0	51
166	Expression Levels of Protein Kinase C-α in Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2004, 6, 184-189.	2.6	44
167	Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. Journal of Pathology, 2004, 202, 321-329.	4.5	108
168	L-Type Amino Acid Transporter-1 Overexpression and Melphalan Sensitivity in Barrett's Adenocarcinoma. Neoplasia, 2004, 6, 74-84.	5.3	59
169	The Molecular Basis of Pancreatic Fibrosis. Pancreas, 2004, 29, 254-263.	1.1	90
170	Gene Expression Profiling of Endocrine Tumors Using DNA Microarrays: Progress and Promise. Endocrine Pathology, 2003, 14, 107-116.	9.0	13
171	Proteomic analysis of elF-5A in lung adenocarcinomas. Proteomics, 2003, 3, 496-504.	2.2	41
172	Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene, 2003, 22, 7950-7957.	5.9	81
173	Accurate Molecular Classification of Human Cancers Based on Gene Expression Using a Simple Classifier with a Pathological Tree-Based Framework. American Journal of Pathology, 2003, 163, 1985-1995.	3.8	64
174	Distinct Transcriptional Profiles of Adrenocortical Tumors Uncovered by DNA Microarray Analysis. American Journal of Pathology, 2003, 162, 521-531.	3.8	338
175	Cytochrome P450 CYP3A4/5 Expression as a Biomarker of Outcome in Osteosarcoma. Journal of Clinical Oncology, 2003, 21, 2481-2485.	1.6	86
176	Protein profiles associated with survival in lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 13537-13542.	7.1	262
177	Overexpression of Oncoprotein 18 Correlates with Poor Differentiation in Lung Adenocarcinomas. Molecular and Cellular Proteomics, 2003, 2, 107-116.	3.8	73
178	Clinical Impact of Recent Advances in the Biology of Adrenocortical Cancer., 2003, 13, 470-478.		2
179	Discordant Protein and mRNA Expression in Lung Adenocarcinomas. Molecular and Cellular Proteomics, 2002, 1, 304-313.	3.8	813
180	Pitfalls in the surgical treatment of insulinoma. Surgery, 2002, 132, 1040-1049.	1.9	35

#	Article	IF	Citations
181	Proteomic Analysis of Cytokeratin Isoforms Uncovers Association with Survival in Lung Adenocarcinoma. Neoplasia, 2002, 4, 440-448.	5.3	74
182	Transforming properties of a Q18â†'E mutation of the microtubule regulator Op18. Cancer Cell, 2002, 2, 217-228.	16.8	29
183	Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells. Cell Death and Differentiation, 2002, 9, 274-286.	11.2	35
184	Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nature Medicine, 2002, 8, 816-824.	30.7	1,788
185	Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clinical Cancer Research, 2002, 8, 788-93.	7.0	69
186	Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clinical Cancer Research, 2002, 8, 2298-305.	7.0	230
187	Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Research, 2002, 62, 4722-9.	0.9	321
188	RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clinical Cancer Research, 2002, 8, 3803-12.	7.0	83
189	Identification and Management of Intravagal Parathyroid Adenoma. World Journal of Surgery, 2001, 25, 419-423.	1.6	26
190	Organ-Specific Molecular Classification of Primary Lung, Colon, and Ovarian Adenocarcinomas Using Gene Expression Profiles. American Journal of Pathology, 2001, 159, 1231-1238.	3.8	180
191	Pathologic, Immunohistochemical, and Molecular Features of Benign and Malignant Phyllodes Tumors of the Breast. Modern Pathology, 2001, 14, 185-190.	5.5	113
192	An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 9824-9829.	7.1	286
193	Overexpression of CXC Chemokines by an Adrenocortical Carcinoma: A Novel Clinical Syndrome. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3968-3974.	3.6	38
194	Overexpression of CXC Chemokines by an Adrenocortical Carcinoma: A Novel Clinical Syndrome. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3968-3974.	3.6	11
195	Granular-cell tumor of trachea masquerading as hurthle-cell neoplasm on fine-needle aspirate: A case report., 2000, 22, 379-382.		14
196	Genetic Changes in Chromosomes 1p and 17p in Thyroid Cancer Progression. Endocrine Pathology, 2000, 11, 137-144.	9.0	32
197	Squamous Cell Carcinoma of the Thyroid: An Aggressive Tumor Associated with Tall Cell Variant of Papillary Thyroid Carcinoma. Modern Pathology, 2000, 13, 742-746.	5.5	86
198	$1\hat{l}\pm$ ,25-Dihydroxyvitamin D3 Up-Regulates Bcl-2 Expression and Protects Normal Human Thyrocytes from Programmed Cell Death*. Endocrinology, 1999, 140, 1649-1656.	2.8	30

#	Article	IF	CITATION
199	Comparison of genetic alterations in colonic adenoma and ulcerative colitis-associated dysplasia and carcinoma. Human Pathology, 1998, 29, 131-136.	2.0	111
200	Treatment of Micronodular Lung Metastases of Papillary Thyroid Cancer: Are the Tumors too Small for Effective Irradiation from Radioiodine?. Thyroid, 1998, 8, 215-221.	4.5	27
201	Spontaneous vocal cord paresis and return to normocalcemia: An unusual presentation of parathyroid adenoma with concomitant abscess. Surgery, 1997, 121, 704-707.	1.9	10
202	131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. , 1996, 78, 2184-2192.		64
203	Differential immunohistochemical detection of transforming growth factor $\hat{l}\pm$ , amphiregulin and CRIPTO in human normal and malignant breast tissues. , 1996, 65, 51-56.		95
204	Optimization of the hygromycin B resistance-conferring gene as a dominant selectable marker in mammalian cells. Gene, 1990, 88, 285-288.	2.2	32
205	Regulation of coliphage T3 and T7 RNA polymerases by the lac represser-operator system. Gene, 1989, 84, 209-219.	2.2	57
206	Three Endocrine Neoplasms: An Unusual Combination of Pheochromocytoma, Pituitary Adenoma and Papillary Thyroid Carcinoma. Thyroid, 0, , 111227205407003.	4.5	0